The LPLUNC1 (Long Palate, Lung, and Nasal Epithelium Carcinoma-Associated Protein 1) antibody is a tool used to study the BPIFA1 protein, encoded by the *BPIFA1* gene. LPLUNC1. also known as SPLUNC1 or BPIFA1. belongs to the BPI fold-containing protein family, which shares structural homology with bactericidal/permeability-increasing protein (BPI). It is predominantly expressed in the upper respiratory tract, oral mucosa, and salivary glands, playing roles in innate immunity and mucosal defense. The protein is implicated in antimicrobial activity, inflammation modulation, and maintenance of epithelial barrier integrity.
Antibodies against LPLUNC1 are utilized to investigate its expression patterns and functional mechanisms in diseases such as chronic rhinosinusitis, cystic fibrosis, and COPD. Studies suggest LPLUNC1 interacts with pathogens, regulates ion transport, and influences airway surface liquid composition. Its dysregulation is linked to chronic inflammation and infection susceptibility.
These antibodies enable detection via Western blotting, immunohistochemistry, or ELISA, aiding in biomarker research and therapeutic target exploration. Recent work also examines LPLUNC1’s potential in cancer, particularly head and neck malignancies, where it may suppress tumorigenesis. Overall, LPLUNC1 antibodies are critical for unraveling its dual role in host defense and disease pathology.